GSK has announced an up to $800 million investment to bring drug-substance manufacturing and additional drug-product manufacturing capabilities to the company’s site in Marietta, Pennsylvania, making it the company’s largest US manufacturing investment to date. This expansion will double the size and capacity of the Marietta site. 

The new facility will be capable of manufacturing sterile liquid vaccines and medicines. This facility will also house an R&D pilot plant to manufacture medicines for clinical trials. Additionally, GSK will establish a new vaccines drug-substance facility at the site, dedicated to manufacturing products based on the company’s Multiple Antigen Presenting System (MAPS), a vaccine technology platform. 

Construction of the new facilities is expected to start by the end of this year (2024). The drug-substance facility is anticipated to be operational by the end of 2027, with the drug-product facility following by the end of 2028. Since 2017, GSK has invested close to $1.3 billion in US-based. manufacturing capabilities. 

Source: GSK